Search for: "AMGEN INC."
Results 201 - 220
of 704
Sorted by Relevance
|
Sort by Date
5 Jul 2016, 10:00 pm
Post By Blog Staff On Tuesday, the Federal Circuit sustained an injunction preventing generic drug maker Apotex, Inc. from selling a similar version of Amgen Inc's Neulasta drug without a 180 day notice period after being approved by the FDA. [read post]
7 Jun 2008, 3:34 am
Included on our list were Cephalon, Inc., which spent $512,000, Abbott Laboratories, which spent $880,000, and Amgen Inc., which spent $2.5 million. [read post]
14 Apr 2022, 8:59 pm
By Donald Zuhn –- Earlier today, the Federal Circuit reversed the Final Written Decision, and reconsideration of that decision, by the U.S. [read post]
3 Dec 2023, 9:15 am
It seems likely that Amgen Inc. v. [read post]
2 Feb 2022, 4:15 am
Inc., 941 F.3d 1149 (Fed. [read post]
3 Dec 2023, 9:15 am
It seems likely that Amgen Inc. v. [read post]
6 Dec 2018, 9:41 pm
Amgen Inc. (2017); Impression Products, Inc. v. [read post]
15 Sep 2008, 3:40 am
Amgen, Inc. et al.3:08-cv-00112; filed September 8, 2008 in the Southern District of Iowa Infringement of U.S. [read post]
12 Mar 2008, 8:49 am
Today's Wall Street Journal has another piece on potential further restrictions on anemia drugs sold by Amgen, Inc. and Johnson & Johnson (see Byron's post for the earlier article). [read post]
24 Jul 2023, 6:55 am
Amgen Inc., 2023 WL 4681569, No. 2:22-cv-05326-RGK-MARx (C.D. [read post]
22 Apr 2014, 7:17 pm
The petition of the day is: Amgen Inc. v. [read post]
8 Nov 2016, 8:23 pm
Amgen Inc. 16-332 Issues: (1) Whether the U.S. [read post]
12 Mar 2020, 2:36 pm
Amgen Inc., Civil Action No. 17-1407-CFC, Consolidated (D.Del. [read post]
27 Apr 2023, 11:51 am
The pending Supreme Court case of Amgen Inc. v. [read post]
23 Jan 2014, 6:19 am
John Fund, Inc. [read post]
6 Jun 2017, 9:04 pm
By Andrew Williams -- On May 25, 2017, the FDA's Oncologic Drug Advisory Committee recommended approval of biologics license application ("BLA") 125545 submitted by Hospira Inc., a Pfizer company, for Retacrit, a proposed biosimilar to Amgen Inc.'s Epogen/Procrit (epoetin alfa). [read post]
11 Apr 2014, 9:42 pm
Amgen Inc., and preparing now for the strict litigation timelines once the first applications are filed; • Integrating the monumental changes under the AIA including inter partes review and post-grant review into your biosimilars prosecution and litigation strategies; •... [read post]
27 Nov 2022, 8:10 pm
Paul Berghoff of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Larry Coury of Regeneron Pharmaceuticals, Inc.; Stephanie Donahue of Sanofi; Henry Hadad of Bristol-Meyers Squibb Co.; and Stuart Watt of Amgen, Inc. that will discuss the issues and arguments concerning the current state of enablement and written description law and where the law may be headed. [read post]
16 Apr 2010, 11:55 am
That’s not the case, however, at Amgen, Inc., (AMGN) the recipient of today’s coveted footnoted gold star. [read post]
22 Nov 2006, 9:00 am
Court of Appeals for the Federal Circuit's decision to deny rehearing en banc in Amgen Inc. v. [read post]
